CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
临床工作中克服 CAR-T 细胞耐药的策略：单中心经验
英文原题：Strategies to overcome CAR-T cell resistance in clinical work: A single-institute experience.
查看英文原题
Strategies to overcome CAR-T cell resistance in clinical work: A single-institute experience.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞治疗的出现改变了恶性肿瘤治疗格局，尤其是靶向CD19的CAR-T 用于复发/难治性（R/R）B细胞恶性肿瘤。尽管CAR-T 疗效可观，仍有部分患者对治疗耐药，后续治疗选择有限，因此亟需克服耐药的策略。本研究回顾了3例CAR-T 治疗耐药的R/R弥漫性大B细胞淋巴瘤患者；在接受帕博利珠单抗、21D4 CAR-T 细胞或伊布替尼联合维奈克拉治疗后，患者疾病得到控制。文章还讨论了一些有前景的耐药预防和治疗策略。
展开英文摘要原文
The emergence of chimeric antigen receptor (CAR) T cell therapy has shifted the paradigm of malignant tumor treatment, especially the advent of CD19-directed CAR-T cell therapy for the treatment of relapsed/refractory (R/R) B-cell malignancies. Although CAR-T cell therapy has promising effects, some patients are resistant to this treatment, leaving them with limited options.
Therefore, strategies to overcome resistance to CAR-T cell therapy are needed.
We retrospectively studied three R/R diffuse large B-cell lymphoma patients who were resistant to CAR-T cell therapy and whose disease was controlled after receiving pembrolizumab, 21D4 CAR-T cells, or ibrutinib and venetoclax. Some promising prevention and treatment strategies to overcome treatment resistance are also discussed.
论文信息
- 作者
- Nan F、Fu X、Chen X、Li L、Li X、Wu J、Feng X、Wu X
- 单位
- Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.China
- 期刊
- Frontiers in immunology2022
- 原文标识
- PubMed 36032118 · DOI 10.3389/fimmu.2022.929221
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →